Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue.
Osteosarcoma Drugs in Development market research report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.
Key Targets in the Osteosarcoma Pipeline Market
The key targets in the Osteosarcoma pipeline market are Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 1, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, DNA Topoisomerase II, Fibroblast Growth Factor Receptor 1, and Platelet Derived Growth Factor Receptor Beta. Vascular Endothelial Growth Factor Receptor 2 has the highest number of pipeline products.
Osteosarcoma Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Osteosarcoma Pipeline Market
The key MoA in the Osteosarcoma pipeline market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, DNA Topoisomerase II Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor and Fibroblast Growth Factor Receptor 1 Inhibitor. Vascular Endothelial Growth Factor Receptor 2 Inhibitor has the maximum number of pipeline products.
Osteosarcoma Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Osteosarcoma Pipeline Market
The key RoA in the Osteosarcoma pipeline market are intravenous, oral, subcutaneous, intravenous drip, parenteral, intratumor, intradermal, and inhalational. Intravenous has the majority number of pipeline products.
Osteosarcoma Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Osteosarcoma Pipeline Market
The key molecule types in the Osteosarcoma pipeline market are small molecule, monoclonal antibody, gene-modified cell therapy, cell therapy, oncolytic virus, gene therapy, and monoclonal antibody conjugated.
Osteosarcoma Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Osteosarcoma Pipeline Market
The key companies in the Osteosarcoma pipeline market are AstraZeneca Plc, Bristol-Myers Squibb Co, Exelixis Inc, Advenchen Laboratories LLC, AntiCancer Inc, Atlanthera, Bayer AG, and CSPC Pharmaceutical Group Ltd. AstraZeneca Plc has the highest pipeline products.
Osteosarcoma Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
| Key targets | Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 1, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, Platelet Derived Growth Factor Receptor Beta, DNA Topoisomerase II, and Fibroblast Growth Factor Receptor 1 |
| Key MoA | Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, DNA Topoisomerase II Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, and Fibroblast Growth Factor Receptor 1 Inhibitor |
| Key RoA | Intravenous, Oral, Subcutaneous, Intravenous Drip, Parenteral, Intratumor, Intradermal, and Inhalational |
| Key molecule type | Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, Cell Therapy, Oncolytic Virus, Gene Therapy, And Monoclonal Antibody Conjugated |
| Key companies | AstraZeneca Plc, Bristol-Myers Squibb Co, Exelixis Inc, Advenchen Laboratories LLC, AntiCancer Inc, Atlanthera, Bayer AG, and CSPC Pharmaceutical Group Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology)
- The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
- The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects
- The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology)
- Classify potential new clients or partners in the target demographic
- Develop tactical initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics
- Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline
Actuate Therapeutics Inc
ADCendo ApS
Advanced BioDesign
Advaxis Inc
Advenchen Laboratories LLC
Allarity Therapeutics A/S
Anagenics Ltd
AntiCancer Inc
APEIRON Biologics AG
API Co Ltd
Astex Therapeutics Ltd
AstraZeneca Plc
Atlanthera
Aurora BioPharma Inc
Autolus Therapeutics Plc
Bayer AG
Bicycle Therapeutics Plc
BioAtla Inc
BioEclipse Therapeutics Inc
BioMarck Pharmaceuticals Ltd
BioMed Valley Discoveries Inc
Boehringer Ingelheim International GmbH
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
CanBas Co Ltd
Cellectar Biosciences Inc
Cellestia Biotech AG
Chia Tai Tianqing Pharmaceutical Group Co Ltd
CorMedix Inc
CSPC Pharmaceutical Group Ltd
Curamir Therapeutics Inc
Dnatwo Inc
Eisai Co Ltd
Eleison Pharmaceuticals LLC
ENB Therapeutics LLC
Epeius Biotechnologies Corp
Exelixis Inc
GlaxoSmithKline Plc
GlycoMimetics Inc
Guangzhou Sinogen Pharmaceutical Co Ltd
Hebei Senlang Biotechnology Co Ltd
Hillstream BioPharma Inc
HRYZ (ShenZhen) Biotech Co
Hutchison MediPharma Ltd
Idera Pharmaceuticals Inc
ImmunityBio Inc
Incuron
Innova Therapeutics Inc
Intezyne Inc
Iovance Biotherapeutics Inc
Ipsen SA
Isofol Medical AB
Iterion Therapeutics Inc
ITM Isotopen Technologien Munchen AG
Jiangsu Hengrui Medicine Co Ltd
Joint Biosciences Ltd
K-Group Beta Inc
Komipharm International Co Ltd
Kyowa Kirin Co Ltd
MacroGenics Inc
Mana Therapeutics Inc
MD Biosciences GmbH
MediaPharma SRL
MedPacto Inc
Merck & Co Inc
Merck KGaA
MetCure Therapeutics LLC
Moleculin Biotech Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
Nkarta Inc
Novartis AG
Oncolys BioPharma Inc
Oncotelic Therapeutics Inc
Ono Pharmaceutical Co Ltd
Orgenesis Inc
OS Therapies LLC
Peel Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Pimera Inc
Provectus Biopharmaceuticals Inc
QSAM Therapeutics Inc
Radiopharm Theranostics Ltd
Reven Holdings Inc
Scancell Holdings Plc
Secura Bio Inc
Shanghai De Novo Pharmatech Co Ltd
Shionogi & Co Ltd
Singh Biotechnology LLC
Sorrento Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Taithera Inc
Transcode Therapeutics Inc
Umoja BioPharma Inc
United Therapeutics Corp
Vaccinex Inc
Veana Therapeutics LLC
Y-mAbs Therapeutics Inc
Zentalis Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Osteosarcoma pipeline drugs market?
The key targets in the Osteosarcoma pipeline market are Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 1, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, DNA Topoisomerase II, Platelet Derived Growth Factor Receptor Beta, and Fibroblast Growth Factor Receptor 1.
-
What are the key mechanisms of action in the Osteosarcoma pipeline market?
The key MoA in the Osteosarcoma pipeline market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, DNA Topoisomerase II Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, and Fibroblast Growth Factor Receptor 1 Inhibitor.
-
What are the key RoA in the Osteosarcoma pipeline market?
The key RoA in the Osteosarcoma pipeline market are intravenous, oral, subcutaneous, intravenous drip, parenteral, intratumor, intradermal, and inhalational.
-
What are the key molecule types in the Osteosarcoma pipeline market?
The key molecule types in the Osteosarcoma pipeline market are small molecule, monoclonal antibody, gene-modified cell therapy, cell therapy, oncolytic virus, gene therapy, and monoclonal antibody conjugated.
-
What are the key companies in the Osteosarcoma pipeline drugs market?
In the Osteosarcoma pipeline market the key companies are AstraZeneca Plc, Bristol-Myers Squibb Co, Exelixis Inc, Advenchen Laboratories LLC, AntiCancer Inc, Atlanthera, Bayer AG, and CSPC Pharmaceutical Group Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Oncology reports